Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease.

Nature 2017 03 22;543(7643):108-112. Epub 2017 Feb 22.

Division of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 45229, USA.

Gaucher disease is caused by mutations in GBA1, which encodes the lysosomal enzyme glucocerebrosidase (GCase). GBA1 mutations drive extensive accumulation of glucosylceramide (GC) in multiple innate and adaptive immune cells in the spleen, liver, lung and bone marrow, often leading to chronic inflammation. The mechanisms that connect excess GC to tissue inflammation remain unknown. Here we show that activation of complement C5a and C5a receptor 1 (C5aR1) controls GC accumulation and the inflammatory response in experimental and clinical Gaucher disease. Marked local and systemic complement activation occurred in GCase-deficient mice or after pharmacological inhibition of GCase and was associated with GC storage, tissue inflammation and proinflammatory cytokine production. Whereas all GCase-inhibited mice died within 4-5 weeks, mice deficient in both GCase and C5aR1, and wild-type mice in which GCase and C5aR were pharmacologically inhibited, were protected from these adverse effects and consequently survived. In mice and humans, GCase deficiency was associated with strong formation of complement-activating GC-specific IgG autoantibodies, leading to complement activation and C5a generation. Subsequent C5aR1 activation controlled UDP-glucose ceramide glucosyltransferase production, thereby tipping the balance between GC formation and degradation. Thus, extensive GC storage induces complement-activating IgG autoantibodies that drive a pathway of C5a generation and C5aR1 activation that fuels a cycle of cellular GC accumulation, innate and adaptive immune cell recruitment and activation in Gaucher disease. As enzyme replacement and substrate reduction therapies are expensive and still associated with inflammation, increased risk of cancer and Parkinson disease, targeting C5aR1 may serve as a treatment option for patients with Gaucher disease and, possibly, other lysosomal storage diseases.

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature21368DOI Listing
March 2017
36 Reads
10 Citations
42.351 Impact Factor

Publication Analysis

Top Keywords

gaucher disease
20
tissue inflammation
12
innate adaptive
8
complement activation
8
adaptive immune
8
c5a generation
8
igg autoantibodies
8
c5ar1 activation
8
activation
6
disease
6
c5ar1
5
gcase
5
inflammation
5
gaucher
5
mice
5
inhibition gcase
4
deficiency associated
4
pharmacological inhibition
4
gcase deficiency
4
gcase associated
4

References

(Supplied by CrossRef)

MK Pandey et al.
Mol. Genet. Metab. 2014

L van Dussen et al.
Orphanet J. Rare Dis. 2014

E Aflaki et al.
Aging Cell 2016

J Gervas-Arruga et al.
PLoS One 2015

PK Mistry et al.
Crit. Rev. Oncog. 2013

G Bultron et al.
J. Inherit. Metab. Dis. 2010

YH Xu et al.
Am. J. Pathol. 2003

M Kolev et al.
Nat. Rev. Immunol. 2014

A Klos et al.
Pharmacol. Rev. 2013

MG Strainic et al.
Immunity 2008

DJ Weaver Jr et al.
Eur. J. Immunol. 2010

Similar Publications